Biosimilars – Market Events And Forecast – Overview Of Biosimilars Forecasts
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in these therapy areas totaled approximately $15 billion. Throughout our 2021-2031 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
Biosimilars - Market Events And Forecast - Overview Of Biosimilars Forecasts
Overview of biosimilar forecasts
Key drivers and barriers to biosimilars in the major markets
Total major-market reference brand and biosimilar market shares: 2031
Total major-market reference brand and biosimilar market shares
Biosimilar erosion
Example of the erosion of biologics' uptake by biosimilar competition
Biosimilar erosion in the major markets
Biosimilar erosion in the major markets: 2021, 2026, 2031
Total major-market reference-brand and biosimilar sales: 2021-2031
Definitions
Biosimilar erosion in the major pharmaceutical markets
Biosimilar and reference-brand sales and total market savings in the major markets: 2021-2031
U.S. sales of reference brands and biosimilars: 2021-2031
Order of biosimilar entry: United States
EU5 sales of reference brands and biosimilars: 2021-2031
Order of biosimilar entry: EU5
Japanese sales of reference brands and biosimilars: 2021-2031
Order of biosimilar entry: Japan
Major-market sales of reference brands and biosimilars: 2021-2031
Sales erosion of major-market reference brands: 2021-2031
Major-market share of biosimilars by region: 2021-2031
Major-market shares of biosimilars by class: 2021-2031
Hamzah Aideed, M.Sc.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.
Yashu Malhotra
Yashu Malhotra, M.Pharm., is an analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.
